Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery

Cassandra Koole, Emilia E. Savage, Arthur Christopoulos, Laurence J Miller, Patrick M. Sexton, Denise Wootten

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological responses to the incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment of type 2 diabetes, owing to the broad range of effects that are mediated upon its activation. These include the promotion of glucose-dependent insulin secretion, increased insulin biosynthesis, preservation of -cell mass, improved peripheral insulin action, and promotion of weight loss. Regulation of GLP-1R function is complex, with multiple endogenous and exogenous peptides that interact with the receptor that result in the activation of numerous downstream signaling cascades. The current understanding of GLP-1R signaling and regulation is limited, with the desired spectrum of signaling required for the ideal therapeutic outcome still to be determined. In addition, there are several single-nucleotide polymorphisms (used in this review as defining a natural change of single nucleotide in the receptor sequence; clinically, this is viewed as a single-nucleotide polymorphism only if the frequency of the mutation occurs in 1% or more of the population) distributed within the coding sequence of the receptor protein that have the potential to produce differential responses for distinct ligands. In this review, we discuss the current understanding of GLP-1R function, in particular highlighting recent advances in the field on ligand-directed signal bias, allosteric modulation, and probe dependence and the implications of these behaviors for drug discovery and development.

Original languageEnglish (US)
Pages (from-to)1234-1244
Number of pages11
JournalMolecular Endocrinology
Volume27
Issue number8
DOIs
StatePublished - Aug 1 2013

Fingerprint

Drug Discovery
Insulin
Single Nucleotide Polymorphism
Ligands
Incretins
Glucagon-Like Peptide 1
Mutation Rate
Type 2 Diabetes Mellitus
Weight Loss
Nucleotides
Hormones
Glucose
Peptides
Glucagon-Like Peptide-1 Receptor
Therapeutics
Population
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Minireview : Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery. / Koole, Cassandra; Savage, Emilia E.; Christopoulos, Arthur; Miller, Laurence J; Sexton, Patrick M.; Wootten, Denise.

In: Molecular Endocrinology, Vol. 27, No. 8, 01.08.2013, p. 1234-1244.

Research output: Contribution to journalArticle

Koole, Cassandra ; Savage, Emilia E. ; Christopoulos, Arthur ; Miller, Laurence J ; Sexton, Patrick M. ; Wootten, Denise. / Minireview : Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery. In: Molecular Endocrinology. 2013 ; Vol. 27, No. 8. pp. 1234-1244.
@article{28b744a03e7e40b4bfe9f56cbb1676fe,
title = "Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological responses to the incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment of type 2 diabetes, owing to the broad range of effects that are mediated upon its activation. These include the promotion of glucose-dependent insulin secretion, increased insulin biosynthesis, preservation of -cell mass, improved peripheral insulin action, and promotion of weight loss. Regulation of GLP-1R function is complex, with multiple endogenous and exogenous peptides that interact with the receptor that result in the activation of numerous downstream signaling cascades. The current understanding of GLP-1R signaling and regulation is limited, with the desired spectrum of signaling required for the ideal therapeutic outcome still to be determined. In addition, there are several single-nucleotide polymorphisms (used in this review as defining a natural change of single nucleotide in the receptor sequence; clinically, this is viewed as a single-nucleotide polymorphism only if the frequency of the mutation occurs in 1{\%} or more of the population) distributed within the coding sequence of the receptor protein that have the potential to produce differential responses for distinct ligands. In this review, we discuss the current understanding of GLP-1R function, in particular highlighting recent advances in the field on ligand-directed signal bias, allosteric modulation, and probe dependence and the implications of these behaviors for drug discovery and development.",
author = "Cassandra Koole and Savage, {Emilia E.} and Arthur Christopoulos and Miller, {Laurence J} and Sexton, {Patrick M.} and Denise Wootten",
year = "2013",
month = "8",
day = "1",
doi = "10.1210/me.2013-1116",
language = "English (US)",
volume = "27",
pages = "1234--1244",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Minireview

T2 - Signal bias, allosterism, and polymorphic variation at the GLP-1R: Implications for drug discovery

AU - Koole, Cassandra

AU - Savage, Emilia E.

AU - Christopoulos, Arthur

AU - Miller, Laurence J

AU - Sexton, Patrick M.

AU - Wootten, Denise

PY - 2013/8/1

Y1 - 2013/8/1

N2 - The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological responses to the incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment of type 2 diabetes, owing to the broad range of effects that are mediated upon its activation. These include the promotion of glucose-dependent insulin secretion, increased insulin biosynthesis, preservation of -cell mass, improved peripheral insulin action, and promotion of weight loss. Regulation of GLP-1R function is complex, with multiple endogenous and exogenous peptides that interact with the receptor that result in the activation of numerous downstream signaling cascades. The current understanding of GLP-1R signaling and regulation is limited, with the desired spectrum of signaling required for the ideal therapeutic outcome still to be determined. In addition, there are several single-nucleotide polymorphisms (used in this review as defining a natural change of single nucleotide in the receptor sequence; clinically, this is viewed as a single-nucleotide polymorphism only if the frequency of the mutation occurs in 1% or more of the population) distributed within the coding sequence of the receptor protein that have the potential to produce differential responses for distinct ligands. In this review, we discuss the current understanding of GLP-1R function, in particular highlighting recent advances in the field on ligand-directed signal bias, allosteric modulation, and probe dependence and the implications of these behaviors for drug discovery and development.

AB - The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological responses to the incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment of type 2 diabetes, owing to the broad range of effects that are mediated upon its activation. These include the promotion of glucose-dependent insulin secretion, increased insulin biosynthesis, preservation of -cell mass, improved peripheral insulin action, and promotion of weight loss. Regulation of GLP-1R function is complex, with multiple endogenous and exogenous peptides that interact with the receptor that result in the activation of numerous downstream signaling cascades. The current understanding of GLP-1R signaling and regulation is limited, with the desired spectrum of signaling required for the ideal therapeutic outcome still to be determined. In addition, there are several single-nucleotide polymorphisms (used in this review as defining a natural change of single nucleotide in the receptor sequence; clinically, this is viewed as a single-nucleotide polymorphism only if the frequency of the mutation occurs in 1% or more of the population) distributed within the coding sequence of the receptor protein that have the potential to produce differential responses for distinct ligands. In this review, we discuss the current understanding of GLP-1R function, in particular highlighting recent advances in the field on ligand-directed signal bias, allosteric modulation, and probe dependence and the implications of these behaviors for drug discovery and development.

UR - http://www.scopus.com/inward/record.url?scp=84880810520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880810520&partnerID=8YFLogxK

U2 - 10.1210/me.2013-1116

DO - 10.1210/me.2013-1116

M3 - Article

C2 - 23864649

AN - SCOPUS:84880810520

VL - 27

SP - 1234

EP - 1244

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 8

ER -